Ertugliflozin/metforminAlternative Names: MK 8835/metformin; MK 8835B
Latest Information Update: 07 Mar 2017
At a glance
- Originator Merck & Co; Pfizer
- Developer Merck & Co
- Class Antihyperglycaemics; Biguanides; Chlorobenzenes; Glycosides; Heterocyclic bicyclo compounds; Phenyl ethers; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Sodium-glucose transporter 2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Type 2 diabetes mellitus